Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01417611
Other study ID # KUMCHSN02
Secondary ID
Status Completed
Phase N/A
First received July 27, 2010
Last updated August 15, 2011
Start date September 2010
Est. completion date June 2011

Study information

Verified date August 2011
Source Konkuk University Hospital
Contact n/a
Is FDA regulated No
Health authority Korea: Ministry for Health and Welfare
Study type Interventional

Clinical Trial Summary

Image-enhanced endoscopy in screening colonoscopy

1. useful tool for detecting subtle epithelial lesions

2. useful tool for predicting real-time histology of epithelial lesions. Among image-enhancing techniques, i-SCAN is new developed and the practical usefulness of i-scan for screening colonoscopy has not been investigated yet.


Description:

New technologies have been developed to enhance the visualization of colorectal mucosa to unmask even minute mucosal lesions and identify neoplastic lesion from non-neoplastic lesions. In particular, there appears to be strong evidence that pan-colonic chromoendoscopy enhances the detection of colorectal neoplasm in the colon and rectum. However, this technique is time-consuming because of both the dye spraying and suction of collected dye in the dependent portion, and therefore it is unsuitable for routine application. To overcome this inconvenience, optical-digital method involves conversion of the optical characteristics of the light used for illumination or imaging with a light source differing in optical characteristics from ordinary white light (WL), such as narrow band imaging (NBI), Fujinon imaging color enhancement (FICE), auto-fluorescence imaging (AFI) and infra-red imaging (IRI).

I-scan technology is the newly developed image enhanced endoscopy technology, classified as a digital contrast method among endoscopic imaging techniques.19 I-scan has three modes of image enhancement, i.e. surface enhancement (SE); contrast enhancement (CE); and tone enhancement (TE). The three modes (SE, CE and TE) are arranged in series, therefore, it is possible to apply two or more of these three modes at one time. Switching the levels or modes of enhancements can be done on a real-time basis, without any time lag by pushing a relevant button, thus enabling efficient endoscopic observation. Furthermore, while NBI) images are much darker than conventional white light (WL) images, i-scan images are as bright as conventional WL images, therefore, i-scan is able to observe much larger areas in a distant view compared with NBI. Consequently, i-scan might be more useful for performing screening endoscopy).

However, the actual usefulness of I-scan in enhancing the detection of colonic neoplastic lesions is not known yet in screening colonoscopy. Therefore, we tried to evaluate the hypothesis that, in subjects undergoing colonoscopy screening, the routine application of i-scan during withdrawal could improve adenoma detection as compared with standard WL examination.


Recruitment information / eligibility

Status Completed
Enrollment 389
Est. completion date June 2011
Est. primary completion date May 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria:

- a consecutive series of asymptomatic average-risk subjects aged 40-75 years who underwent first screening colonoscopy at the Healthcare Center of Konkuk University Medical Center in Seoul, Korea

Exclusion Criteria:

- (i) the colonoscopy did not reach the cecum, (ii) the bowel preparation was poor or inadequate (iii) patients taking anticoagulants that precluded removal of polyps during colonoscopy, (iv) patients had a history of bowel resection, or (v) patients who refused to participate or were unable to provide informed consent to the study (vi) patients with melanosis coli

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Procedure:
i-scan CE, SE, TE mode
I-scan technology is the newly developed image enhanced endoscopy technology, classified as a digital contrast method among endoscopic imaging techniques. I-scan has three modes of image enhancement, i.e. surface enhancement (SE); contrast enhancement (CE); and tone enhancement (TE). The three modes (SE, CE and TE) are arranged in series, therefore, it is possible to apply two or more of these three modes at one time. Switching the levels or modes of enhancements can be done on a real-time basis, without any time lag by pushing a relevant button, thus enabling efficient endoscopic observation.

Locations

Country Name City State
Korea, Republic of Healthcare Center, Digestive Disease Center, Konkuk University Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Konkuk University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary polyp/adenoma detection rate (per-polyp/adenoma analysis and per-patient analysis) To compare the polyp/adenoma detection rate (per-polyp/adenoma analysis and per-patient analysis) among conventional WL, i-scan-CE/SE or i-scan-CE/SE/TE-c groups. up to 24 weeks No
Secondary characterization of polyp To differentiate the adenomatous polyp from non-adenomatous polyp using colonoscopic finding up to 24 weeks No
See also
  Status Clinical Trial Phase
Completed NCT02244632 - Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer Phase 1/Phase 2
Completed NCT02057471 - Intravenous Iron: Measuring Response in Anemic Surgical Patients Phase 4
Terminated NCT01074333 - An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment N/A
Active, not recruiting NCT00506207 - A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy Phase 1
Recruiting NCT05953662 - Safety and Efficacy of Reduced-port Laparoscopic Surgery for Patients Of Colon and Upper Rectal Cancer N/A
Completed NCT01959269 - Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy N/A
Completed NCT03559543 - Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Phase 2
Recruiting NCT04160832 - Prevalence and Spectrum of Cancer Susceptibility Among Patients With Advanced Colorectal Polyps
Terminated NCT02961283 - Study of ASN003 in Subjects With Advanced Solid Tumors Phase 1
Suspended NCT02121405 - Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM Phase 3
Active, not recruiting NCT03936530 - Infrapyloric and Greater Curvature Lymph Node Metastasis in Colon Cancer
Terminated NCT03724071 - Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. Phase 1/Phase 2
Active, not recruiting NCT02882620 - Enhancing Prevention Pathways Toward Tribal Colorectal Health N/A
Completed NCT00906997 - Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy N/A
Completed NCT00188331 - Cognitive Function and Fatigue in Colorectal Cancer (CRC) Patients After Chemotherapy N/A
Completed NCT04786704 - A Stool DNA Test for Detection of Advanced Colorectal Neoplasia in Asymptomatic Chinese Community Population
Terminated NCT02384850 - Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer Phase 1
Completed NCT01288833 - Clinical Study of Real Time Colorectal Polyp Diagnosis During Colonoscopy - the VALID Colonoscopy Study N/A
Completed NCT00001693 - Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers Phase 1
Recruiting NCT03280407 - NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer Phase 2